Amgen Option Alert: Apr 17 $320 Calls at the Bid: 4548 vs 290 OI

Amgen Option Alert: Apr 17 $320 Calls at the Bid: 4548 @ $1.92 vs 290 OI; Ref=$295.9704

Amgen (NASDAQ:AMGN) 株価情報

Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Inc

Revealing a significant insider sell on February 21, Derek Miller, SVP at Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), as per the latest SEC filing.
What Happened: Miller's decision to sell 2,024 shares of Amgen was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000318154/000112760225006112//Archives/edgar/data/318154/000112760225006112/0001127602-25-006112-index.htm">U.S. Securities and Exchange Commission</a> on Friday. The total value of the sale is $593,933.
Monitoring the market, Amgen's shares up by 0.2% at $298.52 during Friday's morning.
<h3>Unveiling the Story Behind Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Understanding the Numbers: Amgen's Finances</h3>
Revenue Growth: Amgen's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 10.86%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 65.75%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Amgen's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 1.17.
</li>
</ul>
Debt Management: Amgen's debt-to-equity ratio stands notably higher than the industry average, reaching 10.23. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 39.41 is lower than the industry average, implying a discounted valuation for Amgen's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 4.82, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 15.59 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000318154">Check Out The Full List Of Amgen's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

AMGN

Derek Miller Takes Money Off The Table, Sells $593K In Amgen Stock

Biotech

General

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFVN

RHHBY

TERN

VANI

VKTX

FDA Says Novo Nordisk's Ozempic Injection .68 mg/1 ml, Injection 1.34 mg/1 ml, Injection 2.68 Mg/1 ml Available As Of Feb 21; Novo Nordisk's Wegovy, Injection, 1.7 mg/.75 ml , Wegovy, Injection, 2.4 mg/.75 ml Now Available; FDA Says Semaglutide Injection Shortage Is Resolved As Of Feb 21

Amgen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NYSE">AMGN</a>) short percent of float has risen 11.27% since its last report. The company recently reported that it has 12.74 million shares sold short, which is 2.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Amgen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739982618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Amgen has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Amgen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Amgen's peer group average for short interest as a percentage of float is 5.26%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Amgen's Recent Short Interest

It was reported on February 14, that Murdo Gordon, EVP at Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) executed a significant insider sell, according to an SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000318154/000112760225004776//Archives/edgar/data/318154/000112760225004776/0001127602-25-004776-index.htm">U.S. Securities and Exchange Commission</a> on Friday outlined that Gordon executed a sale of 8,771 shares of Amgen with a total value of $2,585,644.
Tracking the Friday's morning session, Amgen shares are trading at $293.93, showing a down of 1.02%.
<h3>Unveiling the Story Behind Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Amgen's Financial Performance</h3>
Revenue Growth: Amgen displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 23.18%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 61.07%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Amgen's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 5.27.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 8.02, caution is advised due to increased financial risk.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 39.28 is lower than the industry average, implying a discounted valuation for Amgen's stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 4.81 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 26.76 reflects market recognition of Amgen's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000318154">Check Out The Full List Of Amgen's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVP At Amgen Sells $2.59M Of Stock

Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to $161,431.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $280.0 to $305.0 for Amgen over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 448.17 with a total volume of 924.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $280.0 to $305.0 over the last 30 days.
<h3>Amgen Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739391322_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.45</td>
<td>$3.25</td>
<td>$3.45</td>
<td>$305.00</td>
<td>$107.2K</td>
<td align="right">318</td>
<td align="right">408</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.0</td>
<td>$8.35</td>
<td>$9.0</td>
<td>$300.00</td>
<td>$47.7K</td>
<td align="right">344</td>
<td align="right">53</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.0</td>
<td>$8.95</td>
<td>$9.0</td>
<td>$300.00</td>
<td>$42.3K</td>
<td align="right">344</td>
<td align="right">100</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.5</td>
<td>$13.35</td>
<td>$13.5</td>
<td>$290.00</td>
<td>$33.7K</td>
<td align="right">675</td>
<td align="right">54</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.65</td>
<td>$13.45</td>
<td>$13.5</td>
<td>$290.00</td>
<td>$31.0K</td>
<td align="right">675</td>
<td align="right">85</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Having examined the options trading patterns of Amgen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Amgen</h3>
<ul>
<li>With a volume of 1,356,099, the price of AMGN is down -0.63% at $294.81. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $305.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Underperform rating for Amgen, targeting a price of $275. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Amgen with a target price of $295. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $324. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Amgen, maintaining a target price of $329. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Amgen Unusual Options Activity For February 12

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$75.00</td>
<td>$39.4K</td>
<td>2.1K</td>
<td>8.1K</td>
</tr>
<tr>
<td>AHCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$10.00</td>
<td>$71.4K</td>
<td>0</td>
<td>4.7K</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$105.8K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>COR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$822.5K</td>
<td>495</td>
<td>258</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.00</td>
<td>$81.1K</td>
<td>5.1K</td>
<td>217</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$270.00</td>
<td>$140.0K</td>
<td>355</td>
<td>200</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$390.00</td>
<td>$39.6K</td>
<td>484</td>
<td>151</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$610.00</td>
<td>$53.0K</td>
<td>100</td>
<td>137</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$67.50</td>
<td>$33.6K</td>
<td>1.8K</td>
<td>120</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$860.00</td>
<td>$25.3K</td>
<td>50</td>
<td>112</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 3 day(s) on February 14, 2025. This event was a transfer of 200 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $39.4K, with a price of $197.0 per contract. There were 2192 open contracts at this strike prior to today, and today 8123 contract(s) were bought and sold. 
• Regarding AHCO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>), we observe a put option sweep with bearish sentiment. It expires in 220 day(s) on September 19, 2025. Parties traded 476 contract(s) at a $10.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $71.4K, with a price of $150.0 per contract. There were 0 open contracts at this strike prior to today, and today 4752 contract(s) were bought and sold. 
• For THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we notice a call option sweep that happens to be neutral, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 300 contract(s) at a $145.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $105.8K, with a price of $355.0 per contract. There were 1108 open contracts at this strike prior to today, and today 1040 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a call option trade with bearish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $230.00 strike. The total cost received by the writing party (or parties) was $822.5K, with a price of $3290.0 per contract. There were 495 open contracts at this strike prior to today, and today 258 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 100 contract(s) at a $35.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $812.0 per contract. There were 5109 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option trade that happens to be bullish, expiring in 129 day(s) on June 20, 2025. This event was a transfer of 200 contract(s) at a $270.00 strike. The total cost received by the writing party (or parties) was $140.0K, with a price of $700.0 per contract. There were 355 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 99 contract(s) at a $390.00 strike. This particular put needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $39.6K, with a price of $400.0 per contract. There were 484 open contracts at this strike prior to today, and today 151 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on February 28, 2025. This event was a transfer of 53 contract(s) at a $610.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $53.0K, with a price of $1000.0 per contract. There were 100 open contracts at this strike prior to today, and today 137 contract(s) were bought and sold. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 65 day(s) on April 17, 2025. Parties traded 57 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $590.0 per contract. There were 1841 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bearish, expiring in 157 day(s) on July 18, 2025. This event was a transfer of 4 contract(s) at a $860.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $6340.0 per contract. There were 50 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AHCO

MRNA

10 Health Care Stocks With Whale Alerts In Today's Session

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Overweight and raises the price target from $310 to $329.

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $329

A substantial insider sell was reported on February 7, by Nancy A Grygiel, SVP &amp; CCO at Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), based on the recent SEC filing.
What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000318154/000112760225003500//Archives/edgar/data/318154/000112760225003500/0001127602-25-003500-index.htm">U.S. Securities and Exchange Commission</a> on Friday. The total value is $483,807.
Amgen shares are trading down 0.11% at $297.45 at the time of this writing on Friday morning.
<h3>Discovering Amgen: A Closer Look</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Amgen: Delving into Financials</h3>
Revenue Growth: Over the 3 months period, Amgen showcased positive performance, achieving a revenue growth rate of 23.18% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 61.07%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Amgen's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 5.27.
</li>
</ul>
Debt Management: Amgen's debt-to-equity ratio stands notably higher than the industry average, reaching 8.02. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Amgen's P/E ratio of 39.39 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 4.82 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Amgen's EV/EBITDA ratio of 26.82 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000318154">Check Out The Full List Of Amgen's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Nancy A Grygiel Implements A Sell Strategy: Offloads $483K In Amgen Stock

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group raised Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) price target from $176 to $202. Evercore ISI Group analyst Mark Lipacis maintained an Outperform rating. Arm shares closed at $173.26 on Wednesday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) from $256 to $275. B of A Securities analyst Tim Anderson maintained an Underperform rating. Amgen shares closed at $307.81 on Wednesday. <a href="https://www.benzinga.com/quote/AMGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital boosted Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) price target from $233 to $260. BMO Capital analyst Rufus Hone maintained an Outperform rating. Fiserv shares closed at $229.53 on Wednesday. <a href="https://www.benzinga.com/quote/FI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised the price target for Coherent Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) from $105 to $115. Rosenblatt analyst Mike Genovese maintained a Neutral rating. Coherent shares closed at $90.10 on Wednesday. <a href="https://www.benzinga.com/quote/COHR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Northland Capital Markets cut the price target for CSG Systems International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGS#NASDAQ">CSGS</a>) from $78 to $80. Northland Capital Markets analyst Nehal Chokshi reiterated an Outperform rating. CSG Systems shares closed at $61.66 on Wednesday. S<a href="https://www.benzinga.com/quote/CSGS/analyst-ratings">ee how other analysts view this stoc</a>k.</li>
<li>Piper Sandler slashed Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) price target from $85 to $70. Piper Sandler analyst Harsh Kumar maintained a Neutral rating. Skyworks shares settled at $87.08 on Wednesday. <a href="https://www.benzinga.com/quote/SWKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) price target from $158 to $153. Barclays analyst Lauren Lieberman maintained an Overweight rating. PepsiCo shares closed at $145.66 on Wednesday. <a href="https://www.benzinga.com/quote/PEP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) price target from $80 to $75. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. Hologic shares closed at $72.80 on Wednesday.  <a href="https://www.benzinga.com/quote/HOLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised the price target for Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from $300 to $310. Goldman Sachs analyst Kash Rangan maintained a Buy rating. Workday shares settled at $276.17 on Wednesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) price target from $82 to $80. Piper Sandler analyst Thomas Champion maintained an Overweight rating. Uber shares closed at $64.48 on Wednesday. <a href="https://www.benzinga.com/quote/UBER/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></li>
</ul>

Pre-Market Outlook

COHR

CSGS

HOLX

SWKS

UBER

WDAY

Uber To $80? Here Are 10 Top Analyst Forecasts For Thursday

B of A Securities analyst Tim Anderson maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Underperform and raises the price target from $256 to $275.

B of A Securities Maintains Underperform on Amgen, Raises Price Target to $275

Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from <a href="https://www.benzinga.com/25/02/43494246/private-employment-rises-by-183000-beats-estimates-in-january-consumer-facing-industries-drove-hiring">positive labor market data.</a>
The S&amp;P 500 gained 0.3% to 6,045 points, while the Dow Jones Industrial Average rose 0.6%, now trading less than 1% below its all-time high.
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) missed quarterly earnings expectations on its cloud business, triggering a 7% drop, its worst single-day decline in a year. On the upside, Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) surged 6% after beating estimates, fueling a rally in chip stocks. Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) also gained 3.4%.
The Russell 2000 outperformed with a 0.9% gain, reflecting strength in smaller-cap stocks.
Fresh labor market data signaled resilience. Private sector employment rose by 183,000 in January according to the ADP report, surpassing expectations of 150,000. The services sector continued expanding,<a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43499292/us-services-growth-slows-in-january-as-tariff-concerns-mount"> as per ISM survey</a>, though at a slightly slower-than-anticipated pace.
Investors piled into Treasuries, sending yields tumbling across the curve. The 30-year yield fell to its lowest level since Dec. 18, 2024, while the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rallied 1.9%.
Gold extended its bull run, surging over 1% to a record $2,870 per ounce, driven by continued central bank buying. Copper jumped 2%. 
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged down 1.2% to $97,000. 
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>• Russell 2000</td>
<td>2,310.94</td>
<td>0.9%</td>
</tr>
<tr>
<td>• Dow Jones</td>
<td>44,801.97</td>
<td>0.6%</td>
</tr>
<tr>
<td>• S&amp;P 500</td>
<td>6,054.99</td>
<td>0.3%</td>
</tr>
<tr>
<td>• Nasdaq 100</td>
<td>21,621.68</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 2:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.3% to $602.97.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.5% to $447.60.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;inched 0.2% up to $525.63.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1% to $229.09.</li>
<li>The&nbsp;Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 1.6%; the&nbsp;Communication Services Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
Stocks reacting on earnings reports included: 
<ul>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): up 5.9%</li>
<li>Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>): down 2.4%</li>
<li>Mondelez International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>): up 0.62%</li>
<li>Simon Property Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>): 3.55%</li>
<li>Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>): up 5.7%</li>
<li>Snap Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NASDAQ">SNAP</a>): down 6.55%</li>
<li>IDEX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>): down 9.61%</li>
<li>Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>): down 1.77%</li>
<li>Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>): down 7.31%</li>
<li>Fiserv Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>): up 7.48%</li>
<li>Boston Scientific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>): up 1.87%</li>
<li>Illinois Tool Works Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>): down 0.62%</li>
<li>Emerson Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>): down 2.61%</li>
<li>T. Rowe Price Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>): down 3.91%</li>
<li>Cencora Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>): up 0.83%</li>
<li>CDW Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>): up 4.54%</li>
<li>Ares Management Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>): down 2.51%</li>
<li>Bunge Global SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>): down 5.05%</li>
<li>Johnson Controls International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>): up 12.49%</li>
<li>Old Dominion Freight Line Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>): up 5.60%</li>
<li>Stanley Black &amp; Decker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>): down 1.43%</li>
<li>Ares Capital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>): down 3.26%</li>
<li>Criteo SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>): up 17.73%</li>
<li>Timken Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>): up 2.86%</li>
<li>Performance Food Group Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>): down 1.91%</li>
<li>New York Times Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYT#NYSE">NYT</a>): down 11.56%</li>
<li>Griffon Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFF#NYSE">GFF</a>): up 9.00%</li>
<li>Harley-Davidson Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>): down 0.63%</li>
<li>Capri Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>): down 13.94%</li>
<li>Azenta Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZTA#NASDAQ">AZTA</a>): up 1.04%</li>
<li>Vishay Intertechnology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSH#NYSE">VSH</a>): up 8.65%</li>
<li>Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>): up 0.82%</li>
</ul>
Large-cap stocks slated to report earnings after the close are Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), McKesson Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), O&#8217;Reilly Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>), MetLife Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>), Cognizant Technology Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>), Corteva Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>), Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), Skyworks Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>), Aflac Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>), Align Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>). 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43503385/trumps-gaza-plan-for-seaside-resort-faces-global-pushback">Trump&#8217;s Plan To Turn Gaza Into Seaside Resort, Remove 2 Million Palestinians Roundly Rejected By World Leaders</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Macro Economic Events

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Tech

ETFs

$BTC

ALGN

ARCC

ARES

AVGO

AZTA

CMRE

CPRI

CRTO

CTSH

CTVA

SPDR Dow Jones Industrial Average ETF Trust

GOOGL

MDLZ

NVDA

ODFL

ORLY

PFGC

QCOM

REYN

RSVR

SNAP

TECH

iShares Trust Barclays 20+ Year Treasury Bond Fund

TROW

XLRE

Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?

On Tuesday, Amgen&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) reported fourth-quarter sales of $9.10 billion, up 11% year-over-year, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $8.9 billion</a>.
<ul>
<li>Product sales grew 11%, primarily driven by 14% volume growth. Excluding sales from the Horizon Therapeutics acquisition, product sales grew 10%, driven by 15% volume growth.</li>
<li>Ten products delivered at least double-digit sales growth in the fourth quarter, including Repatha (evolocumab), Blincyto (blinatumomab), Tezspire (tezepelumab-ekko), Evenity (romosozumab-aqqg) and Tavneos (avacopan).</li>
<li>The performance included $1.2 billion of sales from rare disease products, driven by several early-in-lifecycle medicines, including Tepezza (teprotumumab-trbw), Krystexxa (pegloticase), Uplinza (inebilizumab-cdon) and Tavneos.</li>
</ul>
Amgen reported adjusted EPS of $5.31, beating <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43477892/amgen-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">the consensus of $5.08</a>.
In its earnings release, the company said the FDA placed a clinical hold on its Phase 1 study of AMG 513 for obesity.
"Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four therapeutic areas," said&nbsp;Robert Bradway, chairman and chief executive officer.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43062677/fda-approves-amgen-treatment-for-pretreated-colorectal-cancer-with-certain-mutation" rel="noreferrer noopener">FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation</a>
Guidance: Amgen expects fiscal year 2025 revenue of $34.3 billion—$35.7 billion versus a consensus of $34.5 billion. The company expects adjusted EPS of $20-$21.20, compared to a consensus of $20.88.
Goldman Sachs is encouraged by the quarter and the company's growth prospects for 2025, which eases concerns about the stock.
Analyst Salveen Richter remains positive as the company continues to perform well, especially as investors recognize the value of MariTide in obesity and diabetes, along with upcoming approvals like Uplizna for IgG4-RD and gMG.
William Blair analyst Matt Phipps says the 2025 outlook mostly aligns with expectations, but R&amp;D spending and operating margin forecasts highlight ongoing investment in late-stage drugs, particularly MariTide and olpasiran.
William Blair analyst writes, "We believe continued growth of key assets, including Repatha, Tezspire, Evenity, Blincyto, and Imdelltra, combined with three biosimilar launches in 2025, will offset headwinds from biosimilar launches of Prolia and Xgeva, providing top-line growth combined with meaningful clinical readouts in 2025&#8230;"
Price Action: AMGN stock is up 5.41% at $304.65 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43498181/cdw-delivers-robust-q4-earnings-targets-continued-market-outperformance-in-2025" target="_blank" rel="noreferrer noopener">IT Company CDW Q4 Earnings: Sales Climb, AI Focus, Stock Buyback Boost &amp; More</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Earnings

Guidance

Health Care

Movers

Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead

High-rolling investors have positioned themselves bullish on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in AMGN often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Amgen. This is not a typical pattern.
The sentiment among these major traders is split, with 66% bullish and 0% bearish. Among all the options we identified, there was one put, amounting to $25,560, and 8 calls, totaling $578,729.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $320.0 for Amgen during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 1031.71 with a total volume of 3,367.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $250.0 to $320.0 over the last 30 days.
<h3>Amgen 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738770325_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$21.0</td>
<td>$20.3</td>
<td>$20.81</td>
<td>$285.00</td>
<td>$252.8K</td>
<td>4.5K</td>
<td align="right">964</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$20.9</td>
<td>$20.25</td>
<td>$20.7</td>
<td>$285.00</td>
<td>$92.9K</td>
<td>4.5K</td>
<td align="right">365</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.7</td>
<td>$10.2</td>
<td>$10.25</td>
<td>$320.00</td>
<td>$58.4K</td>
<td>624</td>
<td align="right">462</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$10.9</td>
<td>$10.45</td>
<td>$10.7</td>
<td>$300.00</td>
<td>$53.5K</td>
<td>982</td>
<td align="right">249</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$21.25</td>
<td>$19.7</td>
<td>$20.8</td>
<td>$285.00</td>
<td>$35.3K</td>
<td>4.5K</td>
<td align="right">407</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Amgen</h3>
<ul>
<li>With a trading volume of 1,699,750, the price of AMGN is up by 5.44%, reaching $304.74.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 85 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Amgen</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $299.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Amgen, which currently sits at a price target of $280. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Amgen, targeting a price of $298. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Amgen, maintaining a target price of $295. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $324. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Amgen Options Trading: A Deep Dive into Market Sentiment

WIIM

Amgen shares are trading higher after the company on Tuesday reported Q4 financial results. The stock initially fell on the report but reversed on Wednesday.

Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) announced its Q4 earnings on Tuesday, February 4, 2025 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Amgen beat estimated earnings by 5.0%, reporting an EPS of $5.31 versus an estimate of $5.08.
Revenue was up $890.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
In the previous quarter, the company beat on EPS by $0.47, resulting in a 1.0% increase change in the share price the following day.
Here's a look at Amgen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>5.11</td>
<td>5</td>
<td>3.87</td>
<td>4.62</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.58</td>
<td>4.97</td>
<td>3.96</td>
<td>4.71</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>8.52B</td>
<td>8.33B</td>
<td>6.94B</td>
<td>8.13B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>8.50B</td>
<td>8.39B</td>
<td>7.45B</td>
<td>8.20B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Amgen <a href="https://www.benzinga.com/quote/AMGN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Amgen Earnings Report: Q4 Overview

Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) just disclosed its Q4 earnings on Tuesday, February 4, 2025 at 04:01 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Amgen beat estimated earnings by 5.0%, reporting an EPS of $5.31 versus an estimate of $5.08.
Revenue was up $890.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.47, leading to a 1.0% increase share price change the next day.
Here's a look at Amgen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>5.11</td>
<td>5</td>
<td>3.87</td>
<td>4.62</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.58</td>
<td>4.97</td>
<td>3.96</td>
<td>4.71</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>8.52B</td>
<td>8.33B</td>
<td>6.94B</td>
<td>8.13B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>8.50B</td>
<td>8.39B</td>
<td>7.45B</td>
<td>8.20B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Amgen <a href="https://www.benzinga.com/quote/AMGN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: Amgen Q4

Amgen shares are trading lower. The company reported Q4 financial results.

Amgen Sees FY25 Revenue $34.3B-$35.7B Vs $34.533B Estimate; Sees Adj. EPS $20-$21.20 Vs $20.88 Estimate

Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) reported quarterly earnings of $5.31 per share which beat the analyst consensus estimate of $5.08 by 4.53 percent. This is a 12.74 percent increase over earnings of $4.71 per share from the same period last year. The company reported quarterly sales of $9.10 billion which beat the analyst consensus estimate of $8.88 billion by 2.51 percent. This is a 11.03 percent increase over sales of $8.20 billion the same period last year.

Earnings Beats

Amgen Q4 2024 Adj EPS $5.31 Beats $5.08 Estimate, Sales $9.10B Beat $8.88B Estimate

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the <a href="https://www.benzinga.com/news/econ-s">world&#8217;s two largest economies.</a>
China responded to President Donald Trump&#8216;s 10% import tariff with targeted countermeasures, including restrictions on key mineral exports to the U.S. and tariffs on American energy products.
Beijing is raising tariffs by 10%-15% on select U.S. imports, including coal, liquefied natural gas, crude oil, agricultural machinery and vehicles. Additionally, China added PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) and Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) to its &#8220;Unreliable Entity List,&#8221; citing the need to &#8220;safeguard national sovereignty, security, and development interests,&#8221; and opened an antitrust investigation on Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>).
Market participants had anticipated a call between Trump and Chinese President Xi Jinping on Tuesday, but media reports indicated the conversation would not happen today.
The trade developments had an immediate impact on oil markets, with West Texas Intermediate crude futures plunging 3% overnight to as low as $70 per barrel. 
Yet, prices rebounded sharply Tuesday morning following reports that Trump is considering issuing a memorandum aimed at inflicting <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43469234/trump-prepares-maximum-pressure-on-iran-oil-jumps-above-73-energy-stocks-rally">maximum economic damage on Iran</a>, potentially leading to a sharp decline in Iranian oil production.
Energy stocks outperformed on the day, while utilities lagged. 
Among individual stocks, Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) rocketed 22% after posting strong earnings and a revenue beat. 
In the commodities market, gold added more than 1%, extending its all-time high, and silver jumped 2.2%. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) declined 2% to $99,000.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,281.54</td>
<td>1.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,495.31</td>
<td>0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,029.97</td>
<td>0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,501.00</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.5% to $600.53.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.1% higher to $444.77.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.9% to $522.81.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1.1% to $226.80.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.9%; the&nbsp;Utilities Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.8%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
Stocks reacting to earnings report included: 
<ul>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): down 1.53%</li>
<li>PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): down 4.43%</li>
<li>Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): down 10.49%</li>
<li>PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): down 11.57%</li>
<li>Archer-Daniels-Midland Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>): down 3.58%</li>
<li>KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>): down 7.90%</li>
<li>Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>): up 3.81%</li>
<li>Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>): down 0.99%</li>
<li>Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>): up 5.85%</li>
<li>Estee Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>): down 16.35%</li>
<li>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>): down 2.78%</li>
<li>Fox Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>): up 4.00%</li>
<li>Ametek Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>): down 1.00%</li>
<li>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>): up 5.85%</li>
<li>Ferrari NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>): up 7.62%</li>
<li>Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>): up 10.46%</li>
<li>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>): up 4.71%</li>
<li>Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>): down 2.72%</li>
<li>Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>): down 1.51%</li>
<li>Gartner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>): up 0.77%</li>
<li>Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>): down 3.41%</li>
<li>Atkore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>): down 20.50%</li>
<li>Berry Global Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>): up 4.15%</li>
<li>WEC Energy Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>): down 1.52%</li>
<li>Hubbell Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>): down 0.55%</li>
<li>TransDigm Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>): down 1.60%</li>
<li>Graphic Packaging Holding Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>): down 1.76%</li>
<li>CNH Industrial NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNHI#NYSE">CNHI</a>): up 1.71%</li>
<li>Ingredion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>): down 6.12%</li>
<li>ATI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>): up 7.02%</li>
<li>Ball Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>): down 8.03%</li>
<li>Lancaster Colony Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>): up 9.27%</li>
<li>Premier Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>): down 15.36%</li>
<li>MPLX LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>): up 2.92%</li>
<li>Oaktree Specialty Lending Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCSL#NASDAQ">OCSL</a>): down 3.42%</li>
<li>PJT Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJT#NYSE">PJT</a>): up 12.77%</li>
<li>Energizer Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENR#NYSE">ENR</a>): down 4.45%</li>
<li>Silicon Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>): down 1.05%</li>
<li>Hamilton Lane Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>): down 0.01%</li>
<li>Madison Square Garden Sports Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>): down 3.74%</li>
<li>Pentair Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>): down 1.89%</li>
<li>Amcor Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>): up 3.87%</li>
<li>Inmode Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>): up 2.82%</li>
<li>Willis Towers Watson Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>): down 3.54%</li>
<li>Axalta Coating Systems Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>): up 7.86%</li>
<li>Mesa Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>): up 10.48%</li>
</ul>
Major companies reporting their earnings after the close are Alphabet Inc., Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Mondelez International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Prudential Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>), Simon Property Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>), Atmos Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>), Aspen Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>), Carlisle Cos. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>), Fair Isaac Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), Jack Henry &amp; Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>), Idex Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>) and Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>).
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43468887/robert-f-kennedy-nomination-advances-to-full-senate-vaccine-stocks-drop">Robert F. Kennedy&#8217;s Health Secretary Nomination Advances To Full Senate: Vaccine Stocks Drop</a></li>
</ul>
Photo: Marek Masik via Shutterstock

Global

AMCR

ARMK

ATKR

AXTA

AZPN

BALL

BERY

CNHI

ENPH

FICO

FOXA

GOOG

HLNE

HUBB

ILMN

INGR

INMD

JKHY

LANC

MLAB

MPLX

MSGS

OCSL

PINC

PLTR

PYPL

RACE

REGN

SLAB

SPOT

US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?

Dividends

Press Releases

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND

Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer

AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

deCODE genetics: Complete recombination map of the human-genome, a major step in genetics

AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

Comments

Amgen

Unusual Options Activity for

ニュース

パートナーシップ

ベンジンガ・グローバル